Tscan Therapeutics Inc (TCRX) — Strategic Asset Allocation Index
Tscan Therapeutics Inc (TCRX) has a Strategic Asset Allocation Index of 35.7% as of June 2023. Strategic assets (PP&E of $68.03 Million plus long-term investments of $-) total $68.03 Million, measured against net assets of $190.61 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See how leveraged is Tscan Therapeutics Inc's balance sheet to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Tscan Therapeutics Inc Strategic Asset Allocation Index (2019–2022)
This chart shows how Tscan Therapeutics Inc's Strategic Asset Allocation Index has evolved across 3 annual periods from 2019 to 2022. As of June 2023, the index stands at 35.7%, representing strategic assets of $68.03 Million against net assets of $190.61 Million USD. For live market cap and overall valuation, see Tscan Therapeutics Inc (TCRX) total market value.
Annual Strategic Asset Allocation Index for Tscan Therapeutics Inc (2019–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Tscan Therapeutics Inc from 2019 to 2022, covering 3 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See TCRX net asset value for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 10.2% | $10.10 Million | $10.10 Million | $- | $99.43 Million | ▲ +2.8 pp |
| 2021 | 7.3% | $11.77 Million | $11.77 Million | $- | $160.78 Million | ▼ -7.7 pp |
| 2019 | 15.1% | $6.41 Million | $6.41 Million | $- | $42.54 Million | — |